The ENCIRCLE Trial (ENCIRCLE)

October 5, 2026 updated by: Edwards Lifesciences

SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.

Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a prospective single-arm, multicenter study.

Study Type

Interventional

Enrollment (Actual)

786

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Camperdown, Australia, NSW2050
        • Royal Prince Alfred Hospital
    • Queensland
      • Chermside, Queensland, Australia, 4032
        • The Prince Charles Hospital
      • Toronto, Canada, M5B 1W8
        • St. Michael's
      • Vancouver, Canada, V6E 1M7
        • St. Pauls
    • Quebec
      • Québec, Quebec, Canada, G1V 0A6
        • Laval University
      • Petah Tikva, Israel, 4941492
        • Rabin Medical Center
      • Leiden, Netherlands, 2333 ZA
        • Leiden University Medical Center
      • Rotterdam, Netherlands, 3015 CE
        • Rotterdam Erasmus MC
      • London, United Kingdom, EC1A 7BE
        • Saint Bartholomew's Medical Center
      • London, United Kingdom, SE1 7EH
        • Saint Thomas Hospital
    • Alabama
      • Huntsville, Alabama, United States, 35801
        • Heart Center Hospital
    • Arizona
      • Phoenix, Arizona, United States, 85006
        • Banner University Medical Center
      • Phoenix, Arizona, United States, 85013
        • Saint Josephs Hospital Medical Center Dignity Health
    • California
      • La Jolla, California, United States, 92037
        • Scripps Health
      • Los Angeles, California, United States, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, United States, 90017
        • Good Samaritan Hospital
      • Los Angeles, California, United States, 90071
        • Kaiser Sunset LA
      • San Francisco, California, United States, 94109
        • California Pacific Medical Center
    • Colorado
      • Loveland, Colorado, United States, 80538
        • UC Health Northern Colorado (Medical Center of the Rockies)
    • Florida
      • Gainesville, Florida, United States, 32605
        • Cardiac & Vascular Institute Foundation
      • Jacksonville, Florida, United States, 32204
        • Ascension St. Vincent's Hospital
      • Naples, Florida, United States, 34102
        • Naples Community Hospital
      • Sarasota, Florida, United States, 34239
        • Sarasota Memorial Hospital
    • Georgia
      • Atlanta, Georgia, United States, 30308
        • Emory University
      • Atlanta, Georgia, United States, 30309
        • Piedmont Healthcare
    • Illinois
      • Glenview, Illinois, United States, 60026
        • Northshore University Health System
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • University of Kansas
      • Wichita, Kansas, United States, 67226
        • Cardiovascular Research Institute of Kansas (CRIOK)
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70808
        • Our Lady of the Lake Regional Medical Center
    • Maryland
      • Baltimore, Maryland, United States, 21218
        • Medstar Union Memorial Hospital
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Henry Ford
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic
      • Saint Cloud, Minnesota, United States, 56303
        • CentraCare
    • Missouri
      • Kansas City, Missouri, United States, 64111
        • Saint Luke's Kansas City
    • New Hampshire
      • Lebanon, New Hampshire, United States, 03756
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • New Brunswick, New Jersey, United States, 08901
        • Robert Wood Johnson University Hospital
    • New York
      • Buffalo, New York, United States, 14203
        • University of Buffalo
      • New York, New York, United States, 10007
        • Weill Cornell Medicine
    • North Carolina
      • Charlotte, North Carolina, United States, 28204
        • Novant Health and Vascular Institute
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • The Christ Hospital
      • Cleveland, Ohio, United States, 44122
        • Cleveland Clinic Foundation
      • Columbus, Ohio, United States, 43123
        • Mount Carmel East Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73120
        • Oklahoma Heart Hospital
      • Tulsa, Oklahoma, United States, 74104
        • Oklahoma Heart Institute
    • Pennsylvania
      • Mechanicsburg, Pennsylvania, United States, 17050
        • UPMC Heart and Vascular Institute
    • Tennessee
      • Nashville, Tennessee, United States, 37205
        • Saint Thomas Health
    • Texas
      • Austin, Texas, United States, 78705
        • Austin Heart
      • Houston, Texas, United States, 77030
        • UT Memorial Hermann
      • Houston, Texas, United States, 77004
        • HCA Houston Healthcare Medical (SCRI)
    • Utah
      • Murray, Utah, United States, 84107
        • Intermountain Medical Center
    • Virginia
      • Norfolk, Virginia, United States, 23507
        • Sentara Norfolk
      • Roanoke, Virginia, United States, 24014
        • Carilion Roanoke Memorial Hospital
    • Washington
      • Seattle, Washington, United States, 98195
        • University of Washington Seattle

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. 18 years of age or older
  2. MR ≥ 3+
  3. NYHA functional class ≥ II
  4. Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations.
  5. Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment.
  6. The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion Criteria:

  1. Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve
  2. Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve
  3. Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation
  4. Left ventricular ejection fraction <25%
  5. Severe right ventricular dysfunction
  6. Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months
  7. History of heart transplant
  8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
  9. Active bacterial endocarditis within 180 days of the procedure
  10. Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
  11. Myocardial infarction within 30 days of the procedure
  12. Clinically significant untreated coronary artery disease requiring revascularization
  13. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure
  14. Stroke or transient ischemic attack within 90 days of the procedure
  15. Irreversible, severe pulmonary hypertension
  16. Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic outpatient oral steroid use
  17. Renal insufficiency or receiving renal replacement therapy
  18. Liver disease
  19. Planned surgery within the next 12 months
  20. Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure
  21. Active infection requiring current antibiotic therapy
  22. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
  23. Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states
  24. Refusal of blood products
  25. Female who is pregnant or lactating
  26. Estimated life expectancy <12 months due to non-cardiac conditions
  27. Participating in another investigational drug or device study that has not reached its primary endpoint
  28. Subject considered to be part of a vulnerable population

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TMVR - Main Cohort

Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).

During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.

Experimental: TMVR - Failed TEER Registry

Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.

During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.

Experimental: TMVR - MAC Registry

Subjects with mitral annular calcification (MAC) will have TMVR.

During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Non-hierarchical composite of death and heart failure rehospitalization
Time Frame: 1 year

Number of subjects with death and/or heart failure rehospitalization

1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Improvement in NYHA functional class compared to baseline
Time Frame: 1 year

New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.

1 year
Improvement in KCCQ Overall Score compared to baseline
Time Frame: 1 year

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

1 year
Improvement in MR compared to baseline
Time Frame: 1 year

Number of subjects with improved MR compared to baseline

1 year
Decrease in LVEDVi compared to baseline
Time Frame: 1 year

Number of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline

1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: John Webb, MD, St. Paul's Hospital
  • Principal Investigator: Mayra Guerrero, MD, Mayo Clinic
  • Principal Investigator: David Daniels, MD, California Pacific Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 12, 2020

Primary Completion (Estimated)

October 10, 2027

Study Completion (Estimated)

October 10, 2031

Study Registration Dates

First Submitted

November 4, 2019

First Submitted That Met QC Criteria

November 5, 2019

First Posted (Actual)

November 6, 2019

Study Record Updates

Last Update Posted (Actual)

October 6, 2026

Last Update Submitted That Met QC Criteria

October 5, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2018-19

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.